EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Novel targets for mucosal healing in inflammatory bowel disease therapy

Pardis Mansouri, Pegah Mansouri, Esmaeil Behmard, Sohrab Najafipour, Amin Kouhpayeh, Akbar Farjadfar

International Immunopharmacology · 2025-01 · 144 · 113544

DOI: 10.1016/j.intimp.2024.113544 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2025-01. Verfasst von Pardis Mansouri und 5 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran; Department of Medical Biotechnology, Fasa University of Medical Sciences…. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Intestinal Mucosa. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 241 Literaturangaben. Gefördert von: Fasa University of Medical Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory bowel disease (IBD) is a chronic condition affecting the gastrointestinal tract, primarily manifesting as ulcerative colitis (UC) or Crohn's disease (CD). Both inflammation and disruption of the intestinal epithelial barrier are key factors in IBD pathogenesis. Substantial evidence has revealed a significant association between aberrant immune responses and impairment of the intestinal epithelial barrier in IBD pathogenesis. The components of the intestinal epithelium, particularly goblet cells and Paneth cells, are crucial to gut homeostasis, as they secrete mucin, antimicrobial peptides (AMPs), and cytokines. Furthermore, impairment of epithelial integrity, which is regulated by tight junctions, is a hallmark of IBD pathology. While common treatments for IBD, such as anti-inflammatory drugs, target various signaling pathways with varying efficacies, therapeutic approaches focused on mucosal and epithelial barrier healing have been largely neglected. Moreover, high costs, side effects, and insufficient or inconsistent therapeutic outcomes remain major drawbacks of conventional anti-IBD drugs. Recent studies on epithelial barrier regeneration and permeability reduction have introduced promising therapeutic targets, including farnesoid X receptor (FXR), urokinase-type plasminogen activator (uPA)-urokinase-type plasminogen activator receptor (uPAR) interaction, fecal microbiota transplantation (FMT), and insulin receptor (INSR). Notably, the simultaneous targeting of intestinal inflammation and promotion of epithelial barrier healing shows promise for efficient IBD treatment. Future research should explore targeted therapies and combination treatments, including natural remedies, microbiota colonization, stem cell approaches, and computer-aided drug design. It is also crucial to focus on accurate prognosis and developing a thorough understanding of IBD development mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesIntestinal MucosaHumansAnimalsFecal Microbiota TransplantationAnti-Inflammatory AgentsWound HealingMolecular Targeted Therapy

Stichwörter der Autor:innen

InflammationInflammatory bowel diseaseIntestinal epithelial barrierMucosal healing

Substanzen

Anti-Inflammatory Agents

Autor:innen und Institutionen

  • Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran; Department of Medical Biotechnology, Fasa University of Medical Sciences, Fasa, Iran.
  • School of Advanced Technologies in Medicine, Fasa University of Medical Sciences, Fasa, Iran; Zarrin Avaye Kowsar Salamat (ZAX Company), Fasa, Iran.
  • Department of Pharmacology, Faculty of Medicine, Fasa University of Medical Sciences, Fasa, Iran; Zarrin Avaye Kowsar Salamat (ZAX Company), Fasa, Iran. Electronic address: kouhpayeha@gmail.com.
  • Department of Medical Biotechnology, Fasa University of Medical Sciences, Fasa, Iran; Zarrin Avaye Kowsar Salamat (ZAX Company), Fasa, Iran. Electronic address: A.Farjadfar@fums.ac.ir.

Förderung

  • Fasa University of Medical Science

Zitieren

APA

Mansouri, P., Mansouri, P., Behmard, E., Najafipour, S., Kouhpayeh, A., & Farjadfar, A. (2025). Novel targets for mucosal healing in inflammatory bowel disease therapy. International Immunopharmacology, 144, 113544. https://doi.org/10.1016/j.intimp.2024.113544

Vancouver

Mansouri P, Mansouri P, Behmard E, Najafipour S, Kouhpayeh A, Farjadfar A. Novel targets for mucosal healing in inflammatory bowel disease therapy. International Immunopharmacology. 2025;144:113544. doi:10.1016/j.intimp.2024.113544

BibTeX
@article{Mansouri2025,
  author = {Mansouri, Pardis and Mansouri, Pegah and Behmard, Esmaeil and Najafipour, Sohrab and Kouhpayeh, Amin and Farjadfar, Akbar},
  title = {Novel targets for mucosal healing in inflammatory bowel disease therapy},
  journal = {International Immunopharmacology},
  year = {2025},
  volume = {144},
  pages = {113544},
  doi = {10.1016/j.intimp.2024.113544}
}
Kostenlos starten →